Company news

Janux Therapeutics, Inc. news in 2023

Janux Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

November 6, 2023

Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

August 7, 2023

Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

July 16, 2023

Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs

July 16, 2023

Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development

June 4, 2023

Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

May 8, 2023

Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences

April 23, 2023

Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors

April 19, 2023

Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

March 9, 2023

Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference

February 13, 2023

Decks in 2023